IM Biologics
Innovative Medicines based on ImmunoModulatory Biologics
Suwon, South Korea · Founded 2020
- Headquarters
- Suwon
- Employees
- 11–50
- Founded
- 2020
- Business Model
- B2B
- Website
- imbiologics.com
About
IMBiologics (IMB) is a South Korean biopharmaceutical company founded in August 2020, dedicated to developing innovative antibody-based therapeutics for immunology, inflammation, and oncology. Leveraging its proprietary IM-OpDECon antibody modality engineering platform, IMB designs differentiated biologics targeting autoimmune diseases and immuno-oncology with unmet medical needs. The company is headquartered in Suwon, Gyeonggi-do, Korea, and is listed on the KOSDAQ exchange, having achieved a landmark $944.8 million global licensing deal for its lead asset IMB-101.
Summary
IM Biologics is a Biotech company based in Suwon, South Korea, founded in 2020.
Tech & App Stack
2 technologies & apps tracked
Every product and vendor across these categories, with where each signal came from.
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Similar Companies
China's leading blood products manufacturer
IVI-RMA provides fertility treatments and patient-centered reproductive care, combining research,...
Altos Labs combines academic science and industry development to create medicines that restore ce...
inVentiv Health merged with INC Research to form Syneos Health, integrating clinical and commerci...
Specialty pharmaceutical company
BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/im-biologics"><img src="https://indexed.vc/api/badge/company/im-biologics" alt="IM Biologics on Indexed.vc" width="260" height="76" /></a>